$KYNB News

Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35

Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation

Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advancing FG-3246 and Roxadustat with ...

Kyntra Bio, Inc. 2026 Q2 - Results - Earnings Call Presentation

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimate

Kyntra Bio Q2 2026 Earnings Call: Complete Transcript

Kyntra Bio to Report Second Quarter 2026 Financial Results

Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia Patients

Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30